Edward Ramos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Edward Ramos has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Jacqueline Kathleen Kueper
Scripps Research Institute, La Jolla, CA, United States
6 shared publications - Jay A. Pandit
Scripps Research Translational Institute, La Jolla, USA
6 shared publications - Katie Baca-Motes
Scripps Research Institute, La Jolla, CA, United States
6 shared publications - Eric J. Topol
Scripps Research Translational Institute, Scripps Research, La Jolla, USA
5 shared publications - Giorgio Quer
Scripps Research Translational Institute, La Jolla, USA
5 shared publications - Lauren Ariniello
Scripps Research Institute, La Jolla, CA, United States
5 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by JMIR Publications Inc. in JMIR Pediatrics and Parenting
- Vol. 9, e74083
Woebot for Postpartum Mood and Anxiety: Randomized Controlled Trial Evaluating Feasibility, Acceptability, and Preliminary Efficacy of a Mobile Cognitive Behavioral Therapy Intervention
Background: Postpartum psychological distress, ranging from transient mood and anxiety disturbances to full-syndrome postpartum depression, is prevalent. Many postpartum individuals lack access to evidence-based interventions due to stigma and insufficient provider availability. The treatment gap is particularly pronounced among historically marginalized groups, including Black, , and low-income mothers. Digital health interventions offer support to address this. Objective: We aimed to evaluate the feasibility, acceptability, and preliminary efficacy of Woebot for Postpartum Mood and Anxiety (W-PPMA), a smartphone-based relational agent delivering cognitive behavioral therapy–informed psychoeducation to postpartum individuals. Methods: This randomized controlled trial recruited participants from the PowerMom study, a digital platform for maternal health research. Eligible individuals (≥16 y, d =−0.16). Exploratory analyses showed a statistically significant between-group difference in Perceived Stress Scale change at EOI (mean difference −1.59, 95% CI −2.4 to −0.73) and a nonsignificant between-group difference in Edinburgh Postnatal Depression Scale change (mean difference −0.51, 95% CI −1.36 to 0.34). Therapeutic alliance (Working Alliance Inventory–Short Revised) was strongest at baseline among Black participants and those from socioeconomically disadvantaged neighborhoods (Area Deprivation Index ≥75). Participants with a high school or General Educational Development reported the highest satisfaction scores, underscoring accessibility across educational backgrounds. Conclusions: W-PPMA met primary study aims. Preliminary evidence and these findings support W-PPMA, warranting further evaluation in larger trials.
- 9 October 2026
- Published by JMIR Publications Inc. in JMIR Pediatrics and Parenting
- Vol. 9, e74083
Open AccessWoebot for Postpartum Mood and Anxiety: Randomized Controlled Trial Evaluating Feasibility, Acceptability, and Preliminary Efficacy of a Mobile Cognitive Behavioral Therapy Intervention
Background: Postpartum psychological distress, ranging from transient mood and anxiety disturbances to full-syndrome postpartum depression, is prevalent. Many postpartum individuals lack access to evidence-based interventions due to stigma and insufficient provider availability. The treatment gap is particularly pronounced among historically marginalized groups, including Black, , and low-income mothers. Digital health interventions offer support to address this. Objective: We aimed to evaluate the feasibility, acceptability, and preliminary efficacy of Woebot for Postpartum Mood and Anxiety (W-PPMA), a smartphone-based relational agent delivering cognitive behavioral therapy–informed psychoeducation to postpartum individuals. Methods: This randomized controlled trial recruited participants from the PowerMom study, a digital platform for maternal health research. Eligible individuals (≥16 y, d =−0.16). Exploratory analyses showed a statistically significant between-group difference in Perceived Stress Scale change at EOI (mean difference −1.59, 95% CI −2.4 to −0.73) and a nonsignificant between-group difference in Edinburgh Postnatal Depression Scale change (mean difference −0.51, 95% CI −1.36 to 0.34). Therapeutic alliance (Working Alliance Inventory–Short Revised) was strongest at baseline among Black participants and those from socioeconomically disadvantaged neighborhoods (Area Deprivation Index ≥75). Participants with a high school or General Educational Development reported the highest satisfaction scores, underscoring accessibility across educational backgrounds. Conclusions: W-PPMA met primary study aims. Preliminary evidence and these findings support W-PPMA, warranting further evaluation in larger trials.
- Open Access
- 2 June 2026
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 15  (1) , e80263
COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study
Background: Observation of COVID-19 rebound after nirmatrelvir plus ritonavir (NPR) has driven important questions surrounding one of the only direct-acting antiviral treatments for COVID-19. Objective: The objective of this study was to examine the epidemiology of COVID-19 rebound among COVID-19–positive outpatients in the United States who independently decided whether or not to take NPR. Methods: This prospective, decentralized observational cohort study was conducted from August 2022 through December 2023 and included frequent proctored COVID-19 rapid antigen tests and self-report symptom surveys for 15 days. The primary outcome was the incidence of viral and symptom rebound. Secondary outcomes included time to initial viral and symptom clearance, rebound probability among patients who cleared by day 15, and symptom frequency. Results: Of 917 consenting participants, 669 (73%) were eligible for inclusion in the analysis (n=443, 66% in the NPR group; n=226, 34% in the control group). The mean age was 46.1 (SD 12.9) years, 62.6% (n=419) of participants were female, and 49.2% (n=329) had at least one preexisting condition. Overall, 15-day cumulative incidence was higher in the NPR group than the control group for both viral (70/443, 15.8% vs 12/226, 5.3%) and symptom (73/443, 16.5% vs 19/226, 8.4%) rebound. Time to initial viral and symptom clearance was similar between groups, and among those who experienced clearance by day 15, the probability of viral rebound (NPR: 19.1%, 95% CI 15.1%-24.0% vs control: 7%, 95% CI 4.0%-12.6%; P <.001) and symptom rebound (NPR: 47.7%, 95% CI 36.1%-60.8% vs control: 16.9%, 95% CI 10.9%-25.7%; P <.001) was higher in the NPR group than the control group. Conclusions: This study demonstrates that while COVID-19 rebound occurs in both NPR-treated and untreated outpatients, the incidence is higher in the NPR group.
- 2 June 2026
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
- Vol. 15  (1) , e80263
Open AccessCOVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study
Background: Observation of COVID-19 rebound after nirmatrelvir plus ritonavir (NPR) has driven important questions surrounding one of the only direct-acting antiviral treatments for COVID-19. Objective: The objective of this study was to examine the epidemiology of COVID-19 rebound among COVID-19–positive outpatients in the United States who independently decided whether or not to take NPR. Methods: This prospective, decentralized observational cohort study was conducted from August 2022 through December 2023 and included frequent proctored COVID-19 rapid antigen tests and self-report symptom surveys for 15 days. The primary outcome was the incidence of viral and symptom rebound. Secondary outcomes included time to initial viral and symptom clearance, rebound probability among patients who cleared by day 15, and symptom frequency. Results: Of 917 consenting participants, 669 (73%) were eligible for inclusion in the analysis (n=443, 66% in the NPR group; n=226, 34% in the control group). The mean age was 46.1 (SD 12.9) years, 62.6% (n=419) of participants were female, and 49.2% (n=329) had at least one preexisting condition. Overall, 15-day cumulative incidence was higher in the NPR group than the control group for both viral (70/443, 15.8% vs 12/226, 5.3%) and symptom (73/443, 16.5% vs 19/226, 8.4%) rebound. Time to initial viral and symptom clearance was similar between groups, and among those who experienced clearance by day 15, the probability of viral rebound (NPR: 19.1%, 95% CI 15.1%-24.0% vs control: 7%, 95% CI 4.0%-12.6%; P <.001) and symptom rebound (NPR: 47.7%, 95% CI 36.1%-60.8% vs control: 16.9%, 95% CI 10.9%-25.7%; P <.001) was higher in the NPR group than the control group. Conclusions: This study demonstrates that while COVID-19 rebound occurs in both NPR-treated and untreated outpatients, the incidence is higher in the NPR group.
- Open Access
- 3 December 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e77641
Digital Biometrics in Predicting Risk for Obstructive Sleep Apnea and Hypertension: Decentralized, Prospective Cohort Study
Background: Sleep is an important component of human health and can be measured longitudinally using digital activity trackers. Further, decentralized digital research has the potential to provide a real-world picture of sleep in large populations. Objective: This study examined whether longitudinal sleep patterns from activity trackers could predict risk of obstructive sleep apnea (OSA) and hypertension, as defined by the Berlin questionnaire and self-report, respectively. Methods: We recruited adults aged ≥18 years nationwide to join our sleep-focused smartphone-based study, called the Research Framework for Exploring Sleep Health. Our sample of 391 adults predominantly comprised women (68%, 247/364) with a mean age of 48 (SD 13.62) years. Participants were asked to fill out health-related surveys, including the Berlin questionnaire and the Horne-Ostberg questionnaire for chronotype. Participants were asked to link their own activity tracker to the app to collect longitudinal sleep data. Results: We analyzed sleep data from 391 participants; the cohort was predominantly White (65%, 231/353) followed by multiracial (17%, 61/353) and Hispanic or Latino (6.5%, 23/353) participants. Collinearity testing showed that OSA risk and self-reported hypertension could be considered independently. Holding BMI at a fixed value, the odds of having high OSA risk increased by 159% for every 1-hour increase in weekday sleep variability (odds ratio [OR] 2.592, 95% CI 1.613-4.400; P <.001), and the odds of high OSA risk increased by 93% for each 1-hour increase in weekend sleep variability (OR 1.928, 95% CI 1.197-3.094; P= .01). The odds of having high OSA risk increased by 22% for each unit (kg/m 2 ) increase in BMI, holding both weekday and weekend sleep at separate fixed values (OR 1.217, 95% CI 1.153-1.293; P <.001). Controlling for age, sex, and BMI, the odds of endorsing hypertension increased by 71% for every 1-hour increase in weekday sleep variability (OR 1.712, 95% CI 1.062-2.917; P= .03). Conversely, for weekend sleep, the odds of endorsing hypertension increased by 43% for a 1-hour increase in weekend sleep variability (OR 1.432, 95% CI 1.062-1.928; P= .04). Increased sleep variability predicted a high risk for both OSA and hypertension in this decentralized cohort, when using data from the Berlin questionnaire. Conclusions: Our study demonstrates the utility of decentralized digital health studies in sleep research. It highlights the potential of activity trackers to predict risk for OSA and hypertension without requiring other patient information or assessment. Sleep variability is gaining increasing importance in the context of sleep health. Digital devices have the potential to help individuals assess their risk for certain disorders.
- 3 December 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27, e77641
Open AccessDigital Biometrics in Predicting Risk for Obstructive Sleep Apnea and Hypertension: Decentralized, Prospective Cohort Study
Background: Sleep is an important component of human health and can be measured longitudinally using digital activity trackers. Further, decentralized digital research has the potential to provide a real-world picture of sleep in large populations. Objective: This study examined whether longitudinal sleep patterns from activity trackers could predict risk of obstructive sleep apnea (OSA) and hypertension, as defined by the Berlin questionnaire and self-report, respectively. Methods: We recruited adults aged ≥18 years nationwide to join our sleep-focused smartphone-based study, called the Research Framework for Exploring Sleep Health. Our sample of 391 adults predominantly comprised women (68%, 247/364) with a mean age of 48 (SD 13.62) years. Participants were asked to fill out health-related surveys, including the Berlin questionnaire and the Horne-Ostberg questionnaire for chronotype. Participants were asked to link their own activity tracker to the app to collect longitudinal sleep data. Results: We analyzed sleep data from 391 participants; the cohort was predominantly White (65%, 231/353) followed by multiracial (17%, 61/353) and Hispanic or Latino (6.5%, 23/353) participants. Collinearity testing showed that OSA risk and self-reported hypertension could be considered independently. Holding BMI at a fixed value, the odds of having high OSA risk increased by 159% for every 1-hour increase in weekday sleep variability (odds ratio [OR] 2.592, 95% CI 1.613-4.400; P <.001), and the odds of high OSA risk increased by 93% for each 1-hour increase in weekend sleep variability (OR 1.928, 95% CI 1.197-3.094; P= .01). The odds of having high OSA risk increased by 22% for each unit (kg/m 2 ) increase in BMI, holding both weekday and weekend sleep at separate fixed values (OR 1.217, 95% CI 1.153-1.293; P <.001). Controlling for age, sex, and BMI, the odds of endorsing hypertension increased by 71% for every 1-hour increase in weekday sleep variability (OR 1.712, 95% CI 1.062-2.917; P= .03). Conversely, for weekend sleep, the odds of endorsing hypertension increased by 43% for a 1-hour increase in weekend sleep variability (OR 1.432, 95% CI 1.062-1.928; P= .04). Increased sleep variability predicted a high risk for both OSA and hypertension in this decentralized cohort, when using data from the Berlin questionnaire. Conclusions: Our study demonstrates the utility of decentralized digital health studies in sleep research. It highlights the potential of activity trackers to predict risk for OSA and hypertension without requiring other patient information or assessment. Sleep variability is gaining increasing importance in the context of sleep health. Digital devices have the potential to help individuals assess their risk for certain disorders.
- Open Access
- 31 July 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31  (9) , 1-7
Multimodal AI correlates of glucose spikes in people with normal glucose regulation, pre-diabetes and type 2 diabetes
Type 2 diabetes (T2D) is a multifaceted disease associated with several factors, including diet, genetics, exercise, sleep and gut microbiome. Current diagnostic and monitoring methods based on episodic assays like glycated hemoglobin (HbA1c) fail to capture its full complexity. Here, in a prospective cohort of 1,137 participants in the United States, we analyzed multimodal data from 347 deeply phenotyped individuals (174 normoglycemic, 79 prediabetic and 94 T2D). We found significant differences in the distribution of glucose spike metrics among different diabetes states, with longer expected time for spike resolution and higher values of nocturnal hypoglycemia in T2D. We identified significant correlations between mean glucose level and gut microbiome diversity, and between expected time for spike resolution and resting heart rate. Our multimodal glycemic risk profiles, validated in 1,955 normoglycemic and 114 prediabetic individuals from an independent cohort, improved risk stratification by highlighting substantial variability among individuals with the same value of HbA1c. Such a multimodal approach provides a detailed phenotype that can potentially improve T2D prevention, diagnosis and treatment, and is more informative than HbA1c.
- 31 July 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31  (9) , 1-7
Open AccessMultimodal AI correlates of glucose spikes in people with normal glucose regulation, pre-diabetes and type 2 diabetes
Type 2 diabetes (T2D) is a multifaceted disease associated with several factors, including diet, genetics, exercise, sleep and gut microbiome. Current diagnostic and monitoring methods based on episodic assays like glycated hemoglobin (HbA1c) fail to capture its full complexity. Here, in a prospective cohort of 1,137 participants in the United States, we analyzed multimodal data from 347 deeply phenotyped individuals (174 normoglycemic, 79 prediabetic and 94 T2D). We found significant differences in the distribution of glucose spike metrics among different diabetes states, with longer expected time for spike resolution and higher values of nocturnal hypoglycemia in T2D. We identified significant correlations between mean glucose level and gut microbiome diversity, and between expected time for spike resolution and resting heart rate. Our multimodal glycemic risk profiles, validated in 1,955 normoglycemic and 114 prediabetic individuals from an independent cohort, improved risk stratification by highlighting substantial variability among individuals with the same value of HbA1c. Such a multimodal approach provides a detailed phenotype that can potentially improve T2D prevention, diagnosis and treatment, and is more informative than HbA1c.
- Open Access
- 7 April 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e70149
Digital Health Platform for Maternal Health: Design, Recruitment Strategies, and Lessons Learned From the PowerMom Observational Cohort Study
Background: Maternal health research faces challenges in participant recruitment, retention, and data collection, particularly among underrepresented populations. Digital health platforms like PowerMom (Scripps Research) offer scalable solutions, enabling decentralized, real-world data collection. Using innovative recruitment and multimodal techniques, PowerMom engages diverse cohorts to gather longitudinal and episodic data during pregnancy and post partum. Objective: This study aimed to evaluate the design, implementation, and outcomes of the PowerMom research platform, with a focus on participant recruitment, engagement, and data collection across diverse populations. Secondary objectives included identifying challenges encountered during implementation and deriving lessons to inform future digital maternal health studies. Methods: Participants were recruited via digital advertisements, pregnancy apps, and the PowerMom Consortium of more than 15 local and national organizations. Data collection included self-reported surveys, wearable devices, and electronic health records. Anomaly detection measures were implemented to address fraudulent enrollment activity. Recruitment trends and descriptive statistics from survey data were analyzed to summarize participant characteristics, assess engagement metrics, and quantify missing data to identify gaps. Results: Overall, 5617 participants were enrolled from 2021 to 2024, with 69.8% (n=3922) providing demographic data. Of these, 48.5% (2723/5617) were younger than 35 years, 14% (788/5617) identified as Hispanic or Latina, and 13.7% (770/5617) identified as Black or African American. Geographic representation spanned all 50 US states, Puerto Rico, and Guam, with 58.3% (3276/5617) residing in areas with moderate access to maternity care and 16.4% (919/5617) in highly disadvantaged neighborhoods based on the Area Deprivation Index. Enrollment rates increased substantially over the study period, from 55 participants in late 2021 to 3310 in 2024, averaging 99.4 enrollments per week in 2024. Participants completed a total of 17,123 surveys, with 71.8% (4033/5617) completing the Intake Survey and 12.4% (697/5617) completing the Postpartum Survey. Wearable device data were shared by 1168 participants, providing more than 378,000 daily biometric measurements, including activity levels, sleep, and heart rate. Additionally, 96 participants connected their electronic health records, contributing 276 data points such as diagnoses, medications, and laboratory results. Among pregnancy-related characteristics, 28.1% (1578/5617) enrolled during the first trimester, while 15.1% (849/5617) reported information about the completion of their pregnancies during the study period. Among the 913 participants who shared delivery information, 56.1% (n=512) had spontaneous vaginal deliveries and 17.9% (n=163) underwent unplanned cesarean sections. Conclusions: The PowerMom platform demonstrates the feasibility of using digital tools to recruit and engage diverse populations in maternal health research. Its ability to integrate multimodal data sources showcases its potential to provide comprehensive maternal-fetal health insights. Challenges with data completeness and survey attrition underscore the need for sustained participant engagement strategies. These findings offer valuable lessons for scaling digital health platforms and addressing disparities in maternal health research. Trial Registration: ClinicalTrials.gov NCT03085875; https://clinicaltrials.gov/study/NCT03085875
- 7 April 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e70149
Open AccessDigital Health Platform for Maternal Health: Design, Recruitment Strategies, and Lessons Learned From the PowerMom Observational Cohort Study
Background: Maternal health research faces challenges in participant recruitment, retention, and data collection, particularly among underrepresented populations. Digital health platforms like PowerMom (Scripps Research) offer scalable solutions, enabling decentralized, real-world data collection. Using innovative recruitment and multimodal techniques, PowerMom engages diverse cohorts to gather longitudinal and episodic data during pregnancy and post partum. Objective: This study aimed to evaluate the design, implementation, and outcomes of the PowerMom research platform, with a focus on participant recruitment, engagement, and data collection across diverse populations. Secondary objectives included identifying challenges encountered during implementation and deriving lessons to inform future digital maternal health studies. Methods: Participants were recruited via digital advertisements, pregnancy apps, and the PowerMom Consortium of more than 15 local and national organizations. Data collection included self-reported surveys, wearable devices, and electronic health records. Anomaly detection measures were implemented to address fraudulent enrollment activity. Recruitment trends and descriptive statistics from survey data were analyzed to summarize participant characteristics, assess engagement metrics, and quantify missing data to identify gaps. Results: Overall, 5617 participants were enrolled from 2021 to 2024, with 69.8% (n=3922) providing demographic data. Of these, 48.5% (2723/5617) were younger than 35 years, 14% (788/5617) identified as Hispanic or Latina, and 13.7% (770/5617) identified as Black or African American. Geographic representation spanned all 50 US states, Puerto Rico, and Guam, with 58.3% (3276/5617) residing in areas with moderate access to maternity care and 16.4% (919/5617) in highly disadvantaged neighborhoods based on the Area Deprivation Index. Enrollment rates increased substantially over the study period, from 55 participants in late 2021 to 3310 in 2024, averaging 99.4 enrollments per week in 2024. Participants completed a total of 17,123 surveys, with 71.8% (4033/5617) completing the Intake Survey and 12.4% (697/5617) completing the Postpartum Survey. Wearable device data were shared by 1168 participants, providing more than 378,000 daily biometric measurements, including activity levels, sleep, and heart rate. Additionally, 96 participants connected their electronic health records, contributing 276 data points such as diagnoses, medications, and laboratory results. Among pregnancy-related characteristics, 28.1% (1578/5617) enrolled during the first trimester, while 15.1% (849/5617) reported information about the completion of their pregnancies during the study period. Among the 913 participants who shared delivery information, 56.1% (n=512) had spontaneous vaginal deliveries and 17.9% (n=163) underwent unplanned cesarean sections. Conclusions: The PowerMom platform demonstrates the feasibility of using digital tools to recruit and engage diverse populations in maternal health research. Its ability to integrate multimodal data sources showcases its potential to provide comprehensive maternal-fetal health insights. Challenges with data completeness and survey attrition underscore the need for sustained participant engagement strategies. These findings offer valuable lessons for scaling digital health platforms and addressing disparities in maternal health research. Trial Registration: ClinicalTrials.gov NCT03085875; https://clinicaltrials.gov/study/NCT03085875
- Open Access
- 17 March 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Woebot for Postpartum Mood and Anxiety: A Randomized Controlled Trial Evaluating Feasibility, Acceptability, and Preliminary Efficacy of a Mobile CBT Intervention (Preprint)
BACKGROUND Postpartum psychological distress, ranging from transient mood and anxiety disturbances to full-syndrome postpartum depression (PPD), is prevalent. Many postpartum individuals lack access to evidence-based interventions due to stigma and insufficient provider availability. The treatment gap is particularly pronounced among historically marginalized groups, including Black, Hispanic/Latina, and low-income mothers, who face higher PPD prevalence and systemic barriers to care. Digital health interventions offer scalable, accessible, and culturally informed emotional support to address these disparities. OBJECTIVE To evaluate the feasibility, acceptability, and preliminary efficacy of a smartphone application-delivered intervention for managing stress, anxiety, and mood in a diverse postpartum population. METHODS This randomized controlled trial recruited participants from the PowerMom study, a digital platform for maternal health research. Eligible individuals (≥16 years, <3 months postpartum) were randomized to Woebot for Postpartum Mood and Anxiety (W-PPMA) or a waitlist control condition. W-PPMA, an investigational digital mental health intervention, features a relational agent delivering cognitive behavioral therapy (CBT)-based psychoeducation via text-based conversations. Primary outcomes included feasibility, acceptability, and satisfaction at 8-week end-of-intervention (EOI). The secondary outcome was change in self-reported depressive symptoms (PHQ-8) at 8-week EOI among participants with elevated baseline symptoms. Exploratory outcomes included anxiety (GAD-7), perinatal depression (EPDS), stress (PSS), mother-infant bond (MIB), and therapeutic alliance (WAI-SR), assessed at baseline, mid-treatment (4 weeks), EOI, and follow-ups at 12 and 16 weeks. The study followed CONSORT guidelines and received IRB approval. RESULTS Participants (N=267; W-PPMA=144, Waitlist=123) represented diverse sociodemographic, mental health, and pregnancy backgrounds. W-PPMA users engaged with the app a median (Q1, Q3) of 9.0 (5.0, 23.8) days over 4.0 (2.0, 7.0) active weeks and reported high feasibility, acceptance, and satisfaction (URPI-F= 31 (28, 34), URPI-A= 30 (28, 34), CSQ-8= 26 (24, 29)). The secondary outcome indicated a small but favorable effect of W-PPMA on depressive symptoms (Cohen’s d=-0.16). Exploratory analyses showed positive trends in perceived stress (PSS) and perinatal depression (EPDS) at EOI. Therapeutic alliance (WAI-SR) was highest among Black participants and those from socioeconomically disadvantaged neighborhoods (ADI ≥75) at Baseline, and at EOI, among those with military healthcare insurance and socioeconomically disadvantaged neighborhoods (ADI ≥75). Satisfaction (CSQ-8) was highest among those with a high school or GED education, highlighting accessibility. CONCLUSIONS Among a diverse postpartum cohort, W-PPMA demonstrated feasibility, acceptability, and modest preliminary efficacy in reducing depressive symptoms. Exploratory findings suggest broader benefits for stress and mood management. High engagement and satisfaction highlight W-PPMA’s potential as a scalable, accessible, and culturally informed digital mental health tool. These findings underscore its potential to bridge gaps in postpartum mental health care, particularly for marginalized populations. Further research is warranted. CLINICALTRIAL Clinicaltrials.gov NCT05662605
- 17 March 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessWoebot for Postpartum Mood and Anxiety: A Randomized Controlled Trial Evaluating Feasibility, Acceptability, and Preliminary Efficacy of a Mobile CBT Intervention (Preprint)
BACKGROUND Postpartum psychological distress, ranging from transient mood and anxiety disturbances to full-syndrome postpartum depression (PPD), is prevalent. Many postpartum individuals lack access to evidence-based interventions due to stigma and insufficient provider availability. The treatment gap is particularly pronounced among historically marginalized groups, including Black, Hispanic/Latina, and low-income mothers, who face higher PPD prevalence and systemic barriers to care. Digital health interventions offer scalable, accessible, and culturally informed emotional support to address these disparities. OBJECTIVE To evaluate the feasibility, acceptability, and preliminary efficacy of a smartphone application-delivered intervention for managing stress, anxiety, and mood in a diverse postpartum population. METHODS This randomized controlled trial recruited participants from the PowerMom study, a digital platform for maternal health research. Eligible individuals (≥16 years, <3 months postpartum) were randomized to Woebot for Postpartum Mood and Anxiety (W-PPMA) or a waitlist control condition. W-PPMA, an investigational digital mental health intervention, features a relational agent delivering cognitive behavioral therapy (CBT)-based psychoeducation via text-based conversations. Primary outcomes included feasibility, acceptability, and satisfaction at 8-week end-of-intervention (EOI). The secondary outcome was change in self-reported depressive symptoms (PHQ-8) at 8-week EOI among participants with elevated baseline symptoms. Exploratory outcomes included anxiety (GAD-7), perinatal depression (EPDS), stress (PSS), mother-infant bond (MIB), and therapeutic alliance (WAI-SR), assessed at baseline, mid-treatment (4 weeks), EOI, and follow-ups at 12 and 16 weeks. The study followed CONSORT guidelines and received IRB approval. RESULTS Participants (N=267; W-PPMA=144, Waitlist=123) represented diverse sociodemographic, mental health, and pregnancy backgrounds. W-PPMA users engaged with the app a median (Q1, Q3) of 9.0 (5.0, 23.8) days over 4.0 (2.0, 7.0) active weeks and reported high feasibility, acceptance, and satisfaction (URPI-F= 31 (28, 34), URPI-A= 30 (28, 34), CSQ-8= 26 (24, 29)). The secondary outcome indicated a small but favorable effect of W-PPMA on depressive symptoms (Cohen’s d=-0.16). Exploratory analyses showed positive trends in perceived stress (PSS) and perinatal depression (EPDS) at EOI. Therapeutic alliance (WAI-SR) was highest among Black participants and those from socioeconomically disadvantaged neighborhoods (ADI ≥75) at Baseline, and at EOI, among those with military healthcare insurance and socioeconomically disadvantaged neighborhoods (ADI ≥75). Satisfaction (CSQ-8) was highest among those with a high school or GED education, highlighting accessibility. CONCLUSIONS Among a diverse postpartum cohort, W-PPMA demonstrated feasibility, acceptability, and modest preliminary efficacy in reducing depressive symptoms. Exploratory findings suggest broader benefits for stress and mood management. High engagement and satisfaction highlight W-PPMA’s potential as a scalable, accessible, and culturally informed digital mental health tool. These findings underscore its potential to bridge gaps in postpartum mental health care, particularly for marginalized populations. Further research is warranted. CLINICALTRIAL Clinicaltrials.gov NCT05662605
- Open Access
- 16 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Digital Health Platform for Maternal Health: Design, Recruitment Strategies, and Lessons Learned From the PowerMom Observational Cohort Study (Preprint)
BACKGROUND Maternal health research faces challenges in participant recruitment, retention, and data collection, particularly among underrepresented populations. Digital health platforms like PowerMom (Scripps Research) offer scalable solutions, enabling decentralized, real-world data collection. Using innovative recruitment and multimodal techniques, PowerMom engages diverse cohorts to gather longitudinal and episodic data during pregnancy and post partum. OBJECTIVE This study aimed to evaluate the design, implementation, and outcomes of the PowerMom research platform, with a focus on participant recruitment, engagement, and data collection across diverse populations. Secondary objectives included identifying challenges encountered during implementation and deriving lessons to inform future digital maternal health studies. METHODS Participants were recruited via digital advertisements, pregnancy apps, and the PowerMom Consortium of more than 15 local and national organizations. Data collection included self-reported surveys, wearable devices, and electronic health records. Anomaly detection measures were implemented to address fraudulent enrollment activity. Recruitment trends and descriptive statistics from survey data were analyzed to summarize participant characteristics, assess engagement metrics, and quantify missing data to identify gaps. RESULTS Overall, 5617 participants were enrolled from 2021 to 2024, with 69.8% (n=3922) providing demographic data. Of these, 48.5% (2723/5617) were younger than 35 years, 14% (788/5617) identified as Hispanic or Latina, and 13.7% (770/5617) identified as Black or African American. Geographic representation spanned all 50 US states, Puerto Rico, and Guam, with 58.3% (3276/5617) residing in areas with moderate access to maternity care and 16.4% (919/5617) in highly disadvantaged neighborhoods based on the Area Deprivation Index. Enrollment rates increased substantially over the study period, from 55 participants in late 2021 to 3310 in 2024, averaging 99.4 enrollments per week in 2024. Participants completed a total of 17,123 surveys, with 71.8% (4033/5617) completing the Intake Survey and 12.4% (697/5617) completing the Postpartum Survey. Wearable device data were shared by 1168 participants, providing more than 378,000 daily biometric measurements, including activity levels, sleep, and heart rate. Additionally, 96 participants connected their electronic health records, contributing 276 data points such as diagnoses, medications, and laboratory results. Among pregnancy-related characteristics, 28.1% (1578/5617) enrolled during the first trimester, while 15.1% (849/5617) reported information about the completion of their pregnancies during the study period. Among the 913 participants who shared delivery information, 56.1% (n=512) had spontaneous vaginal deliveries and 17.9% (n=163) underwent unplanned cesarean sections. CONCLUSIONS The PowerMom platform demonstrates the feasibility of using digital tools to recruit and engage diverse populations in maternal health research. Its ability to integrate multimodal data sources showcases its potential to provide comprehensive maternal-fetal health insights. Challenges with data completeness and survey attrition underscore the need for sustained participant engagement strategies. These findings offer valuable lessons for scaling digital health platforms and addressing disparities in maternal health research. CLINICALTRIAL ClinicalTrials.gov NCT03085875; https://clinicaltrials.gov/study/NCT03085875
- 16 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDigital Health Platform for Maternal Health: Design, Recruitment Strategies, and Lessons Learned From the PowerMom Observational Cohort Study (Preprint)
BACKGROUND Maternal health research faces challenges in participant recruitment, retention, and data collection, particularly among underrepresented populations. Digital health platforms like PowerMom (Scripps Research) offer scalable solutions, enabling decentralized, real-world data collection. Using innovative recruitment and multimodal techniques, PowerMom engages diverse cohorts to gather longitudinal and episodic data during pregnancy and post partum. OBJECTIVE This study aimed to evaluate the design, implementation, and outcomes of the PowerMom research platform, with a focus on participant recruitment, engagement, and data collection across diverse populations. Secondary objectives included identifying challenges encountered during implementation and deriving lessons to inform future digital maternal health studies. METHODS Participants were recruited via digital advertisements, pregnancy apps, and the PowerMom Consortium of more than 15 local and national organizations. Data collection included self-reported surveys, wearable devices, and electronic health records. Anomaly detection measures were implemented to address fraudulent enrollment activity. Recruitment trends and descriptive statistics from survey data were analyzed to summarize participant characteristics, assess engagement metrics, and quantify missing data to identify gaps. RESULTS Overall, 5617 participants were enrolled from 2021 to 2024, with 69.8% (n=3922) providing demographic data. Of these, 48.5% (2723/5617) were younger than 35 years, 14% (788/5617) identified as Hispanic or Latina, and 13.7% (770/5617) identified as Black or African American. Geographic representation spanned all 50 US states, Puerto Rico, and Guam, with 58.3% (3276/5617) residing in areas with moderate access to maternity care and 16.4% (919/5617) in highly disadvantaged neighborhoods based on the Area Deprivation Index. Enrollment rates increased substantially over the study period, from 55 participants in late 2021 to 3310 in 2024, averaging 99.4 enrollments per week in 2024. Participants completed a total of 17,123 surveys, with 71.8% (4033/5617) completing the Intake Survey and 12.4% (697/5617) completing the Postpartum Survey. Wearable device data were shared by 1168 participants, providing more than 378,000 daily biometric measurements, including activity levels, sleep, and heart rate. Additionally, 96 participants connected their electronic health records, contributing 276 data points such as diagnoses, medications, and laboratory results. Among pregnancy-related characteristics, 28.1% (1578/5617) enrolled during the first trimester, while 15.1% (849/5617) reported information about the completion of their pregnancies during the study period. Among the 913 participants who shared delivery information, 56.1% (n=512) had spontaneous vaginal deliveries and 17.9% (n=163) underwent unplanned cesarean sections. CONCLUSIONS The PowerMom platform demonstrates the feasibility of using digital tools to recruit and engage diverse populations in maternal health research. Its ability to integrate multimodal data sources showcases its potential to provide comprehensive maternal-fetal health insights. Challenges with data completeness and survey attrition underscore the need for sustained participant engagement strategies. These findings offer valuable lessons for scaling digital health platforms and addressing disparities in maternal health research. CLINICALTRIAL ClinicalTrials.gov NCT03085875; https://clinicaltrials.gov/study/NCT03085875
- Open Access
- 6 November 2024
- Published by Springer Nature in Research Square
Coronavirus Disease 2019 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: A Prospective Cohort Study
Observation of COVID-19 rebound after Nirmatrelvir Plus Ritonavir (NPR) has driven important questions surrounding one of the only direct acting antiviral treatments for COVID-19. This prospective cohort study to investigate rebound incidence enrolled 917 COVID-19 positive outpatients via a digital proctored test-to-treat solution. Among 669 included in evaluation 493 intended to take NPR and 176 did not. Participants were provided frequent proctored COVID-19 tests and symptom surveys for 15 days. Time to initial viral or symptom clearance was not different between groups. Overall, 15-day viral rebound was three-fold higher in the NPR group (15.2% vs 5.4%, p <0.001) and symptom rebound was double (16.4% vs 8.4%, p <0.01). Among those experiencing initial symptom resolution, rebound after resolution was notably higher in the NPR group (43.8% vs 17.5%). This study demonstrates that while COVID-19 rebound occurs in both NPR treated and untreated outpatients, the incidence is higher in the NPR group.
- 6 November 2024
- Published by Springer Nature in Research Square
Open AccessCoronavirus Disease 2019 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: A Prospective Cohort Study
Observation of COVID-19 rebound after Nirmatrelvir Plus Ritonavir (NPR) has driven important questions surrounding one of the only direct acting antiviral treatments for COVID-19. This prospective cohort study to investigate rebound incidence enrolled 917 COVID-19 positive outpatients via a digital proctored test-to-treat solution. Among 669 included in evaluation 493 intended to take NPR and 176 did not. Participants were provided frequent proctored COVID-19 tests and symptom surveys for 15 days. Time to initial viral or symptom clearance was not different between groups. Overall, 15-day viral rebound was three-fold higher in the NPR group (15.2% vs 5.4%, p <0.001) and symptom rebound was double (16.4% vs 8.4%, p <0.01). Among those experiencing initial symptom resolution, rebound after resolution was notably higher in the NPR group (43.8% vs 17.5%). This study demonstrates that while COVID-19 rebound occurs in both NPR treated and untreated outpatients, the incidence is higher in the NPR group.
- 19 August 2022
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 28  (12) , 1019-1021
Improving participant representation in the era of digital clinical studies
- 19 August 2022
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 28  (12) , 1019-1021
Improving participant representation in the era of digital clinical studies
- Open Access
- 8 July 2022
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 10  (7) , e39145
The Power of Patient Engagement With Electronic Health Records as Research Participants
Electronic health record (EHR) technology has become a central digital health tool throughout health care. EHR systems are responsible for a growing number of vital functions for hospitals and providers. More recently, patient-facing EHR tools are allowing patients to interact with their EHR and connect external sources of health data, such as wearable fitness trackers, personal genomics, and outside health services, to it. As patients become more engaged with their EHR, the volume and variety of digital health information will serve an increasingly useful role in health care and health research. Particularly due to the COVID-19 pandemic, the ability for the biomedical research community to pivot to fully remote research, driven largely by EHR data capture and other digital health tools, is an exciting development that can significantly reduce burden on study participants, improve diversity in clinical research, and equip researchers with more robust clinical data. In this viewpoint, we describe how patient engagement with EHR technology is poised to advance the digital clinical trial space, an innovative research model that is uniquely accessible and inclusive for study participants.
- 8 July 2022
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 10  (7) , e39145
Open AccessThe Power of Patient Engagement With Electronic Health Records as Research Participants
Electronic health record (EHR) technology has become a central digital health tool throughout health care. EHR systems are responsible for a growing number of vital functions for hospitals and providers. More recently, patient-facing EHR tools are allowing patients to interact with their EHR and connect external sources of health data, such as wearable fitness trackers, personal genomics, and outside health services, to it. As patients become more engaged with their EHR, the volume and variety of digital health information will serve an increasingly useful role in health care and health research. Particularly due to the COVID-19 pandemic, the ability for the biomedical research community to pivot to fully remote research, driven largely by EHR data capture and other digital health tools, is an exciting development that can significantly reduce burden on study participants, improve diversity in clinical research, and equip researchers with more robust clinical data. In this viewpoint, we describe how patient engagement with EHR technology is poised to advance the digital clinical trial space, an innovative research model that is uniquely accessible and inclusive for study participants.